| NCT05445778 | III | High grade serous FRalpha high+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD after second line platinum-based therapy, must have avastin with most recent platinum-based therapy (maintenance) | Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA) | AL, CA, FL, GA, IL, IN, IA, KS, KY, LA, ME, MD, MA, MN, NE, NV, NJ, NY, NC, OH, OK, OR, PA, TN, TX, VA | View Drugs | View Results |
| NCT05887609 | II | High grade serous or endometrioid FRalpha medium or high+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD after most recent platinum-based therapy; BRCA MUT patients must have received prior PARP inhibitor therapy (maintenance) | A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer | CO | View Drugs | View Results |